SkinBioTherapeutics PLC
LSE:SBTX

Watchlist Manager
SkinBioTherapeutics PLC Logo
SkinBioTherapeutics PLC
LSE:SBTX
Watchlist
Price: 17 GBX 1.49% Market Closed
Market Cap: 44m GBX

Wall Street
Price Targets

SBTX Price Targets Summary
SkinBioTherapeutics PLC

Wall Street analysts forecast SBTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SBTX is 29.58 GBX with a low forecast of 29.29 GBX and a high forecast of 30.45 GBX.

Lowest
Price Target
29.29 GBX
72% Upside
Average
Price Target
29.58 GBX
74% Upside
Highest
Price Target
30.45 GBX
79% Upside
SkinBioTherapeutics PLC Competitors:
Price Targets
XGN
Exagen Inc
164% Upside
SPRY
ARS Pharmaceuticals Inc
155% Upside
206650
EuBiologics Co Ltd
67% Upside
ZNTL
Zentalis Pharmaceuticals Inc
296% Upside
GLPG
Galapagos NV
10% Upside
ZEAL
Zealand Pharma A/S
67% Upside
HPHA
Heidelberg Pharma AG
102% Upside
300676
BGI Genomics Co Ltd
23% Upside

Revenue
Forecast

Revenue Estimate
SkinBioTherapeutics PLC

The compound annual growth rate of SkinBioTherapeutics PLC's revenue for the next 2 years is 34%.

N/A
Past Growth
34%
Estimated Growth
Estimates Accuracy
9%
Average Beat

Operating Income
Forecast

Operating Income Estimate
SkinBioTherapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
SkinBioTherapeutics PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SBTX's stock price target?
Price Target
29.58 GBX

According to Wall Street analysts, the average 1-year price target for SBTX is 29.58 GBX with a low forecast of 29.29 GBX and a high forecast of 30.45 GBX.

What is SkinBioTherapeutics PLC's Revenue forecast?
Projected CAGR
34%

The compound annual growth rate of SkinBioTherapeutics PLC's revenue for the next 2 years is 34%.

Back to Top